NCT07194317Completed
A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
New medications that work on gut hormones such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are helping many people lose weight and are now recommended for treating obesity by the NHS. While these treatments are effective for weight loss, we don't yet know how they affect what people eat or their overall nutrition. Understanding diet before, during, and after treatment is important. Traditional ways of tracking diet, like paper food diaries, can be difficult to use and are time consuming for clinicians to interpret and record in clinical notes. Digital tools like MyFood24, Nutritics-Libro, and Intake24 may offer a better way to record what people eat, but we need to find out if they can be easily used in everyday healthcare settings. The FIDGET study will test how well these digital diet tools can be used in clinics and linked with electronic health records. The study will use surveys and group discussions to understand how patients and healthcare professionals feel about using these tools.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 64 (actual)
- First submitted
- 8 Sept 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 13 Mar 2026
- Lead sponsor
- King's College London
- Diseases
- Obesity
- NCT number
- NCT07194317
What you commit to
- Study type: Interventional
- Participants enrolled: 64
- From 1 Sept 2025 to the primary completion date, 13 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adults aged \>18 years
- Living with obesity as diagnosed by healthcare professional.
- Referral to T3WMS at GSTT and currently on the service waiting list
- Eligible for GLP-1 receptor agonist (Wegovy) prescription
- Have an active MyChart account
- Have an email address
- Access to a digital device such as a smart phone, computer or tablet where you can access the internet
- Not following a meal replacement diet, for example soups / shakes
- Able to provide informed consent.
- Able to complete surveys in English.
- Not able to provide informed consent
- Not able to complete surveys in English
- Has an eating disorder
- Taking part in another research trial that involves dietary modification
Who the study is looking for
- Adults aged \>18 years
- Living with obesity as diagnosed by healthcare professional.
- Referral to T3WMS at GSTT and currently on the service waiting list
- Eligible for GLP-1 receptor agonist (Wegovy) prescription
- Have an active MyChart account
- Have an email address
- Access to a digital device such as a smart phone, computer or tablet where you can access the internet
- Not following a meal replacement diet, for example soups / shakes
- Able to provide informed consent.
- Able to complete surveys in English.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guy's and St. Thomas' NHS Trust Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.